Semaglutide Research & Studies
We track 21 published, PubMed-indexed studies for Semaglutide, spanning 2017 to 2024. The research below includes 3 meta-analysiss, 8 reviews, 10 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
3
Meta-Analysiss
8
Reviews
10
Clinical Trials
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Meta-AnalysisKaragiannis T, Malandris K, et al.|Diabetologia|2024
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
ReviewBikou A, Dermiki-Gkana F, et al.|Expert Opin Pharmacother|2024
Clinical Pharmacokinetics of Semaglutide: A Systematic Review.
ReviewYang XD, Yang YY|Drug Des Devel Ther|2024
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
ReviewIrfan H|Curr Probl Cardiol|2024
Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.
ReviewBensignor MO, Arslanian S, Vajravelu ME|Curr Opin Pediatr|2024
Semaglutide for the treatment of obesity.
ReviewChao AM, Tronieri JS, et al.|Trends Cardiovasc Med|2023
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial).
Clinical TrialLincoff AM, Brown-Frandsen K, et al.|N Engl J Med|2023
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Meta-AnalysisTan HC, Dampil OA, Marquez MM|J ASEAN Fed Endocr Soc|2022
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Clinical TrialKadowaki T, Isendahl J, et al.|Lancet Diabetes Endocrinol|2022
Wegovy (semaglutide): a new weight loss drug for chronic weight management.
ReviewSingh G, Krauthamer M, Bjalme-Evans M|J Investig Med|2022
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Clinical TrialDavies M, Færch L, et al.|Lancet|2021
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Clinical TrialFriedrichsen M, Breitschaft A, et al.|Diabetes Obes Metab|2021
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Clinical TrialFrías JP, Auerbach P, et al.|Lancet Diabetes Endocrinol|2021
Safety of Semaglutide.
ReviewSmits MM, Van Raalte DH|Front Endocrinol (Lausanne)|2021
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
ReviewMeier JJ|Front Endocrinol (Lausanne)|2021
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Clinical TrialCapehorn MS, Catarig AM, et al.|Diabetes Metab|2020
Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Meta-AnalysisAndreadis P, Karagiannis T, et al.|Diabetes Obes Metab|2018
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Clinical TrialPratley RE, Aroda VR, et al.|Lancet Diabetes Endocrinol|2018
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Clinical TrialSorli C, Harashima SI, et al.|Lancet Diabetes Endocrinol|2017
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Clinical TrialBlundell J, Finlayson G, et al.|Diabetes Obes Metab|2017
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Clinical TrialDavies M, Pieber TR, et al.|JAMA|2017